EP2385846A2 - Implant médical et procédé de production d'un tel implant - Google Patents

Implant médical et procédé de production d'un tel implant

Info

Publication number
EP2385846A2
EP2385846A2 EP10700942A EP10700942A EP2385846A2 EP 2385846 A2 EP2385846 A2 EP 2385846A2 EP 10700942 A EP10700942 A EP 10700942A EP 10700942 A EP10700942 A EP 10700942A EP 2385846 A2 EP2385846 A2 EP 2385846A2
Authority
EP
European Patent Office
Prior art keywords
grain size
different
implant
layers
regions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10700942A
Other languages
German (de)
English (en)
Inventor
Eckhard Quandt
Christiane Zamponi
Rodrigo Lima De Miranda
Giorgio Cattaneo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acandis GmbH and Co KG
Original Assignee
Acandis GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acandis GmbH and Co KG filed Critical Acandis GmbH and Co KG
Publication of EP2385846A2 publication Critical patent/EP2385846A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/04—Metals or alloys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/02—Inorganic materials
    • A61L31/022—Metals or alloys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings
    • A61L2300/608—Coatings having two or more layers

Definitions

  • the invention relates to a medical implant and a method for producing such an implant.
  • An implant with the features of the preamble of claim 1 is described for example in WO 2007/027251 A2.
  • adhesion promoter layers must be used for this purpose. After degradation of the polymer occurs an uncontrolled absorption of the Body or carrier, which can lead to the separation and detachment of stent areas.
  • the polymer layers are susceptible to mechanical damage when crimped or discharged from a catheter. At the damaged areas, premature absorption of the body occurs. Certain polymer coatings can cause problems with the sterilization of the implant.
  • the invention has for its object to provide a medical implant that allows improved control and slowing down the rate of absorption.
  • the invention is also based on the object of specifying a method for producing such an implant.
  • the object is achieved by the subject matter of claim 1 and with regard to the method by the subject of claim 17.
  • the invention is based on the idea of specifying a medical implant with a body that is at least partially made of at least one biodegradable crystalline material.
  • the body has at least two distinct first and second regions, wherein the crystalline material of the first region has a different grain size than the crystalline material of the second region.
  • the invention is further based on the idea of specifying a method for producing a medical implant in which a base body is coated with at least one biodegradable crystalline material by a PVD method, in particular sputtering, or at least one biodegradable crystalline material in layers to form a self-supporting body is applied such that the grain size of the applied crystalline material is less than 200 microns.
  • the invention is based on the idea of specifying a method for producing a medical implant in which a base body is coated with at least one biodegradable crystalline material by a PVD method, in particular sputtering, or at least one biodegradable crystalline material in layers to form a self-supporting body wherein at least two different first and second regions are formed by the PVD process, in particular by sputtering, and wherein the crystalline material of the first region has a different grain size than the crystalline material of the second region. Training different area with different grain sizes is disclosed and claimed independently of a maximum grain size.
  • the crystalline material is not only used for the production of the main body, but also for coating the base body or for producing a cantilevered body.
  • this is done by a PVD method, that is to say by a method based on the physical vapor deposition, in particular by sputtering.
  • This has the advantage that the material properties, in particular the structural properties of the implant can be very finely adjusted.
  • the grain size of the crystalline material can be controlled well, so that a targeted grain refinement, in particular a targeted grain refining, can be set.
  • a high grain refining i. small grain sizes are achieved, whereby the absorption rate of the implant is lowered.
  • the production of the implant by means of a PVD method, in particular by means of sputtering offers the possibility of changing the material properties in regions, so that the implant can be equipped with regionally different functions.
  • the advantage of the medical implant according to the invention is that the properties of the implant can be selectively controlled as a function of the respective microstructure by setting different particle sizes in different regions of the implant.
  • the setting of different grain sizes in different areas of the implant is particularly well by the use of PVD method, in particular by sputtering, feasible.
  • the at least one region of the implant forms a spatially extended material region which has substantially homogeneous physical properties, for example the dissolution properties of the material.
  • the at least one other region of the implant forms another spatially extended material region which has substantially different homogeneous physical properties, in particular a different dissolution rate of the material.
  • the different material areas are separated from each other in the sense that in one area a grain size and in the other area is a different grain size. They represent discrete regions, in contrast to a microstructure, in which different particle sizes, in particular different mean particle sizes, for example of different alloy components, are mixed in one and the same area.
  • a material area forms a coherent massive fabric area.
  • the fabric region forms, in particular macroscopically, the structure or a part of the structure of the implant, in particular of the implant body.
  • the material areas in particular form part of the implant wall. Specifically, the material areas each form a separate part of the implant wall.
  • the size, extent and shape of the respective region is not limited per se, but adapted such that a property set in the region, for example the dissolution rate, has an influence on the behavior of the implant.
  • the size of the respective area required for this purpose depends on the wall thickness and / or the dimension of the implant or a structural element of the implant formed by the area and can thus be determined by the person skilled in the art, depending on the application and need.
  • the delimitation of a region from another region, in particular from an adjacent other region is effected in particular by the grain size, which differs in the different regions.
  • the material can be single-phase or multi-phase.
  • different areas of the body of the implant can form layers which are arranged on top of each other.
  • the layers have different particle sizes; in concrete terms, the particle size present in one layer differs from the particle size present in another layer, so that different properties, for example different absorption rates, can be set in layers.
  • several layers are subsequently applied one above the other until the desired layer thickness has been reached.
  • the individual material layers of a layer have the same grain size, so that the overall result is a greater layer thickness with a uniform (average) grain size. In this case, a plurality of such multi-layer sputtered layers can be combined with each other, wherein a different grain size is set per layer.
  • the layers may comprise at least one outer layer and one inner layer, wherein the grain size of the material of the outer layer is smaller than the grain size of the material of the inner layer.
  • the outer layer of the implant comes in the body with the body fluid, in particular a vessel wall into contact. Due to the grain refining in the outer layer, the dissolution of the outer layer takes place relatively slow. After the outer layer is completely dissolved, the inner layer is dissolved relatively quickly because its grain size is larger than that of the outer layer.
  • the inner layer in this case forms a middle layer or a core layer, so that the overall result is a sandwich-like structure.
  • the inner layer or middle layer is protected against bodily fluid on both sides by the outer layer, which is arranged radially inward and radially outward.
  • This embodiment is suitable for influencing structural elements or web elements that initially exert a relatively high initial force on the vessel wall during implantation in such a way that the high initial force drops relatively quickly due to the rapidly degradable outer layer. After removal of the outer layer, a relatively thin, less rapidly absorbable layer remains, which, in contrast to the expansion function of the original stake element, essentially only assumes a supporting function.
  • the body comprises more than two layers arranged on top of each other, wherein the grain size of the material of the respective layer increases with increasing distance from the outer layer. This ensures that the absorption rate gradually increases with increasing dissolution of the implant. Again, it is possible to reverse this behavior by the grain size of the material of the respective layer decreases with increasing distance from the outer layer.
  • the layers with the different grain sizes so that the layers on both sides of the middle or core layer have grain sizes which decrease or increase towards the core layer.
  • the properties change layer by layer with increasing resolution.
  • the changes in the absorption rate with increasing dissolution of the implant made possible by the above-explained embodiments, can be used as required and as a treatment objective and combined with one another by providing different regions of the implant with different absorption properties.
  • one or more medicaments are incorporated in at least one layer and / or in an intermediate layer.
  • the invention or the embodiments mentioned above can be extended to drug-delivery implants.
  • the body has a plurality of structural elements, in particular lattice webs.
  • the structural members may generally include stent members, such as the aforementioned grid bars, closed cells, connectors, end sheets, and the like, other functional elements.
  • at least one structural element comprises at least two different regions with different grain sizes and / or one structural element each consists of one region with one grain size and one further structural element each of a further region with a different grain size.
  • whole structural elements differ in terms of their grain size, each structural element in itself having a substantially uniform grain size.
  • there is an entire structural element for example a grid web from the first region with a first grain size.
  • Another structural element forms a second area with a different grain size.
  • the grain size of the first region or first structural element can be greater or smaller than the grain size of the second region or second structural element, depending on at which point of the implant a desired dissolution rate is to be set. It is also possible for a single structural element to have different regions with different particle sizes, so that different dissolution rates can be set within the same structural element. This makes it possible, for example, to cut through a structural element or a lattice web at a desired location in order to prevent the flow of force. In the region of the separation point, the grid web or the structural element has an area with a relatively large grain size, so that this Area is degraded relatively quickly, whereas the remaining area of the structural element remains with finer grain size.
  • first structural elements can be provided, which in the implanted state apply a greater supporting force than second structural elements, the material of the first structural elements having a smaller particle size than the material of the second structural elements.
  • first structural elements are mainly responsible for the application of the support force, in the case of a stent for the application of the radial force to the vessel wall.
  • the second structural elements have a retention function such that the second structural elements counteract an expansion of the diameter of the stent or another implant. The second structural elements therefore form bridges which limit an expansion movement of the implant, in particular of the stent.
  • the second structural elements or bridges are resolved with larger grain sizes quickly.
  • an increase in diameter occurs, so that the first structural elements can unfold their supporting force acting on the vessel wall.
  • an implant can be realized that increases the radial force on the vessel wall with increasing duration of treatment. This can be done, for example, in so-called remodeling, i. be advantageous in the reconstruction of the vessel inner wall.
  • the support force can be reduced by the first support elements are also degraded, but at a slower rate of dissolution than the second support elements.
  • first and second structural elements both contribute to the application of the radial force or the expansion force acting on the vessel wall.
  • the structural elements have layers with different grain sizes. This ensures that the dissolution behavior in the thickness direction, ie normal to the implant surface, changes.
  • the crystalline material may include corrosion trenches such that dissolution of the material in the implanted state occurs along the corrosion trenches, thereby enabling geometrically predetermined resolution of at least some areas of the implant or the complete implant.
  • the various regions may be web-shaped, with the grain size of at least one web-shaped region and the width of the web-shaped region in the ratio 1: 15 to 1: 100. This ensures that the grain size is in any case much smaller than the web width or generally the width of the regions or the structural elements.
  • biodegradable crystalline material As the biodegradable crystalline material or as the biodegradable crystalline materials, magnesium alloys and / or iron alloys may be used.
  • the transition between the regions is discontinuous, wherein the grain size changes abruptly.
  • the transition between the regions may be continuous, with the grain size continuously changing in a transition region between the two regions.
  • the continuous change of the grain size in the transition region between the two regions having the different grain sizes has the advantage that the physical properties, in particular the dissolution speed, between the regions gradually change.
  • the continuous transition graded layers also has a positive influence on the cohesion of the material. There is a particularly good adhesion between the layers when the material properties change continuously.
  • the outer layer envelops the inner layer.
  • the outer layer thus completely surrounds the inner layer or the inner region, that is to say also at the lateral edges of the inner layer or the inner region.
  • the inner layer enveloped by the outer layer forms a core that is shielded from bodily fluid by the outer layer in use.
  • FIG. 1 shows the structure of a structural element, in particular a grid web according to the prior art.
  • FIG. 1a shows the microstructure according to FIG. 1, in which intercrystalline corrosion occurs
  • Fig. 2 shows the structure of a structural element according to an inventive
  • FIG. 3 shows the microstructure of a structural element according to a further embodiment of the invention.
  • FIG. 3 a shows the microstructure according to FIG. 3, in which intercrystalline corrosion occurs
  • FIG. 4 shows the microstructure of a structural element comprising two layers according to an exemplary embodiment of the invention.
  • Fig. 5 is a view of a body of an implant according to an embodiment of the invention with different areas having different grain sizes.
  • the method according to the invention or its embodiments offer an excellent alternative to the conventional techniques used for the production of biologically degradable implants, in particular stents.
  • the PVD methods according to the invention in particular the sputtering processes, allow the setting of very small particle sizes, whereby the absorption rate of the implant material is greatly reduced in comparison to known implant materials.
  • PVD methods or sputtering processes have the advantage that the material properties, in particular the grain size, can be varied in regions, so that the absorption rate in different implant areas can be adjusted differently, so that special properties of the implant can be enhanced, attenuated or readjusted.
  • the resolution of the implant is well controlled.
  • sputtering has the advantage that the distribution of the elements in the alloy can be finely adjusted.
  • Precipitations are avoided in contrast to conventional melting technologies, since the magnesium or the iron can be supersaturated with alloying elements, whereby the dissolution rates can be varied in other limits.
  • the second phases can be better distributed. Furthermore, it is possible to reduce the dissolution rate by the fine, targeted adjustment of the alloys.
  • Sputtering also has the advantage that larger amounts of additional elements or a variety of different additional elements that slow down the resolution, for example, can be introduced into the material, as is possible with conventional melting technologies. In the case of the latter, precipitation processes often occur which adversely affect the mechanical properties of the implant.
  • any thin layers can be formed, which have different properties, especially with regard to the resolution of the implant.
  • the production of bioabsorbierbarer implants by sputtering also has the advantage that the material properties along the implant, ie in the axial, radial and circumferential direction can be changed.
  • the direction of dissolution can be influenced from the inner diameter to the outer diameter, from the web edge to the web core, from the stent ends to the stent center or in each case inversely.
  • intermediate layers can be introduced, which reduce the dissolution rate, so that the faster dissolving core of the implant or of the individual structural elements only begins to dissolve when the intermediate layer has completely degraded.
  • sputtering corrosion trenches can be introduced, so that the resolution first is steered along predefined paths.
  • the sputtering process can be combined, for example, with a lithography process. It is also possible to integrate path-like areas in the implant wall with a relatively large grain size, so that these areas corrode before the surrounding material. It is also possible to subsequently introduce corrosion trenches by etching. The resolution can be controlled by the length of these paths.
  • sputtering and subsequent structuring of the implant for example by etching, web geometries can be defined with which the resolution can be controlled.
  • grain sizes smaller than 200 microns an effective reduction in the dissolution rate is achieved. It is possible to set grain sizes in the range of 2 ⁇ m by sputtering or by other PVD methods. The setting of other grain sizes is possible by sputtering readily. For example, the upper limit for the corrosion-slowing grain size to 175 microns, 150 microns, 125 microns, 100 microns, 75 microns, 50 microns, 25 microns, 20 microns, 15 microns, 10 microns, 8 microns, 6 microns, 4 microns are adjusted.
  • the lower limit depends on the process parameters and may be 2 ⁇ m or less, in particular at least 1.8 ⁇ m, in particular at least 1.6 ⁇ m, in particular at least 1.4 ⁇ m, in particular at least 1.2 ⁇ m, in particular at least 1 ⁇ m, in particular at least 0 , 8 ⁇ m, in particular at least 0.6 ⁇ m, in particular at least 0.4 ⁇ m, in particular at least 0.2 ⁇ m, in particular at least 0.1 ⁇ m.
  • all values mentioned above, including their intermediate values come into consideration.
  • one area may have a grain size of 2 ⁇ m and another area may have a grain size of 20 ⁇ m.
  • Other different regions with different grain sizes may be provided.
  • a third region may have a grain size of 100 ⁇ m. It is also possible that further additional regions have the grain sizes of 200 ⁇ m known and customary in the prior art, so that these regions have a particularly fast resolving power.
  • the method according to the invention is suitable for producing different medical implants which are at least partially biodegradable. Particularly preferred is the process for producing biodegradable stents. It is also possible to use the method of manufacturing filters which are removed after a predetermined time by dissolution. Such filters are used, for example, in the cerebral area to prevent blood particles from clogging cerebral vessels. A common reason for the formation of clots and The following particle detachment is the expansion of a stenosis in the carotid area or the implantation of a heart valve. In the first phase after appropriate treatment, the risk of blood clots is particularly high. At this stage a filter along with anti-clotting therapy is beneficial.
  • anti-coagulant agents may be discontinued if the risk of particle detachment decreases.
  • Such a filter can be produced particularly advantageously with the aid of the method according to the invention or an embodiment of the method.
  • occlusion devices or devices that minimize blood flow or lead to other collateral vessels are used. After completion of the treatment, this device or the occlusion device is to be absorbed in order not to impair the physiological flow in the long term.
  • Such occlusion devices or devices can advantageously be produced with an embodiment of the method according to the invention.
  • the method according to the invention is not restricted to the manufacture on the aforementioned medical implants, but may comprise further implants made of biodegradable materials.
  • At least one biodegradable crystalline material is coated on a base body, in particular by sputtering.
  • Suitable crystalline materials are metals and metal alloys which are biodegradable, for example magnesium or iron or magnesium alloys and / or iron alloys. It is also possible with the method to integrate different materials, in particular two, three or more than three materials, in regions in the implant. Thus, the method is also excellent, different materials cohesively with each other to connect, so that an implant can be produced, which is partially constructed of different materials, in particular different biodegradable materials.
  • the grain size of the applied crystalline material is adjusted so that it is less than 200 microns.
  • the base body, on which the crystalline material is sputtered, may be made at least partially of a biodegradable material.
  • the main body can be formed by other manufacturing methods, for example by laser cutting from a solid material.
  • the base body can have a different microstructure, in particular other particle sizes, than the bioabsorbable crystalline material applied by sputtering to the base body.
  • the crystalline material forms a self-supporting body of the implant, which is produced by sputtering.
  • the support structure of the body is made by sputtering.
  • a main body, as in the previous embodiment, is not required for this purpose.
  • Both methods have in common that at least part of the bioabsorbable implant material is applied by sputtering.
  • implants which are at least partially made of a biodegradable, crystalline material, in particular of a metallic material.
  • the grain boundaries 17 of the grains 18 are shown.
  • the grain size in known implants is substantially greater than the grain size of the implants according to FIGS. 2, 3, of the exemplary embodiments according to the invention.
  • the grain size is the mean grain size. This applies to the entire information in the application concerning the particle size.
  • various methods are available which are known to the person skilled in the art, for example Line cutting method in which grains visible in a flat cut are cut from a measuring line and counted. From the length of the measurement line and the number of grains, the grain size can be determined in a conventional manner. The measurement of the cutting line can be done for example by laser interferometry.
  • the line-cut method is used.
  • the grain size is 200 microns or more. In the implants according to the embodiments of the invention, the grain size is less than 200 microns.
  • FIGS. 1a and 3a The advantage of the invention associated with the smaller grain size or grain refining is illustrated with reference to FIGS. 1a and 3a.
  • the dissolution of the implant material takes place by intercrystalline corrosion or grain boundary corrosion.
  • Fig. Ia it can be seen that the grain boundary decay progresses rapidly for large grains with a grain size of 200 microns or more, whereas the intergranular corrosion in the fine-grained microstructure of FIG. 3a of an implant material according to the invention takes place much slower due to the fine cross-linking.
  • the dissolution rate in the known implant materials with a relatively large particle size is therefore higher than the dissolution rate in an implant according to an embodiment of the invention, in which the material has a smaller particle size.
  • the smaller particle size compared to the prior art is achieved in the implant according to FIG. 3 a or FIG. 2 by the application of the material by sputtering.
  • Another advantage of the fine-grained structure is found in other mechanical properties, such as improved tensile strength and improved fatigue behavior.
  • a microstructure with a particularly small grain size as shown for example in Fig. 3 (about 2 microns)
  • the web width of the stent greatly reduce, without the grains reach the size of the web dimensions, in particular the web width.
  • the ratio between the grain size and the ridge width or generally the ratio between the grain size and the width or thickness of the structural element can be adjusted in a range from 1:15 to 1: 100.
  • the range limits can be varied as follows: On the one hand, range limits can be set starting from the limit 1:15, which is 1:20, 1:25, 1:30, 1:35, 1:40, 1:45, 1 : 50, 1:55, 1:60, 1:65, 1:70, 1:75, 1:80.
  • the above range limits may be combined with the other limit of 1: 100, respectively.
  • the other range limit can be varied or varied as follows, starting from the ratio 1: 100: 1:95, 1:90, 1:85, 1:80, 1:75, 1:70, 1:65, 1: 60, 1:55, 1:50, 1:45, 1:40, 1:35.
  • the range limits mentioned above can each be combined with the other range limit 1:15 and, if appropriate, with the restricted range limits emanating from the range limit 1:15.
  • FIG. 1 Another particular feature of the sputtered implant is shown in FIG. It can be seen there that the body 10 of the implant has at least two different first and second regions 11, 12.
  • a region is generally understood to mean a spatial or layered section of the implant which has essentially homogeneous properties and thereby delimits itself from another second region. This takes place, as shown in FIG. 4, in the body 10 by the different grain sizes of the grains 18 of the first and second regions 11, 12.
  • the regions 11, 12 formed by sputtering are bonded together in a material-locking manner.
  • the various regions 11, 12 may form layers 13, 14, for example, which are arranged on top of each other, as shown in FIG. 4.
  • the individual layers differ by different grain sizes and / or by different materials.
  • two layers may be provided which are prepared by coating a base body or as a cantilever structure by sputtering or another PVD method.
  • the layer thickness of the individual layer 13, 14 is adjusted in a manner known per se by sputtering a suitable number of layers of material one above the other is applied until the desired layer thickness is reached.
  • a substantially uniform average grain size is set per material layer, so that the resulting layer differs by the grain size from another layer, which is also produced by sputtering and applying a suitable number of material layers.
  • the various layers 13, 14 form at least part of the wall of the implant or the complete wall of the implant.
  • the webs are constructed of such layers, which have different rates of dissolution.
  • the structure in layers is possible with the sputtering technique unlike conventionally produced pipes.
  • the stent can apply a very high force immediately after implantation to dilate a stenosis. After dissolution of the first layer after a controlled time remains a stent structure, which applies a much lower force due to the material degradation.
  • the remaining structure fulfills the function of gentle support of the vessel wall or prevents detaching particles from entering the bloodstream.
  • the implant in particular the stent, may comprise at least one layer or a basic structure of a material that is not bioabsorbable, so that a weaker compared to the implant implant implant structure, ie with a smaller wall thickness remains in the body, if desired .
  • the complete implant in particular the complete stent, can consist entirely of bioabsorbable materials or consist of a completely bioabsorbable material, so that a complete dissolution of the stent is achieved after a predetermined time.
  • the layers may comprise an outer layer 13 and an inner layer 14 or a first layer and a second layer, wherein the grain size of the material of the outer layer 13 is smaller than the grain size of the material of the inner layer 14.
  • the outer layer is arranged so that it comes in the implanted state with the vessel wall or generally with body fluid directly in contact. It can be provided that the inner layer is coated on both sides with an outer layer, so that the inner layer does not come into direct contact with body fluid at least until the outer layers are dissolved. In this case, more than one inner layer 14 may be provided, which have different particle sizes.
  • the outer layer 13 has a fine-grained structure and thus forms a relatively slow-dissolving structure.
  • the inner layer it is possible to reverse the dissolution behavior such that a layer having a coarse-grained texture is arranged as the outer layer, so that the dissolution rate is initially relatively fast until the outer layer is dissolved, and then slowed down when the finer-grained inner layer after dissolving the outer layer with the body fluid comes into contact.
  • the inner layer it is possible to form the inner layer as a core layer with a fine-grained structure, which is coated on both sides with outer layers of a relatively coarse-grained microstructure. It can also be provided more than one inner layer.
  • the grain size of the material of the respective layer may increase with increasing distance from the outer layer.
  • the outer layer is relatively fine-grained
  • the first layer arranged further inside has a structure with a slightly larger grain size than the outer layer
  • a second layer arranged on the first layer has a structure whose grain size is greater than the grain size of the first layer is etc.
  • This layer structure can be reversed such that the grain size of the material of the respective layer decreases with increasing distance from the outer layer.
  • the dissolution rate increases as the resolution progresses.
  • the dissolution rate slows down with increasing resolution.
  • FIG. 5 shows a stent with a grid structure.
  • the stent has a body 10 with a plurality of structural elements 15, 16, which in the present case are designed as lattice webs. Different structural elements form different regions with different particle sizes, which are characterized by different line thicknesses.
  • the various regions 11, 12 so-called graded layers in which the grain size, in particular the average grain size between the layers changes continuously.
  • a transition layer or arranged Between two juxtaposed or stacked layers with different grain sizes is a transition layer or arranged a transition region in which the mean grain size changes continuously.
  • the continuously changing grain size of the transition region leads to a continuous transition of the two layers.
  • the physical properties between the two layers change continuously. This particularly concerns the dissolution rate.
  • the distance between the two regions or layers having the different particle sizes, ie the transition region is designed such that at least one mean grain size is present in the transition region, which lies between the different average particle sizes of the two regions or layers which are connected by the transition region are.
  • the distance between the layers can be selected by the skilled person depending on the application. All features of the other embodiments disclosed in this application, in particular all grain size features, are also disclosed and claimed in the context of this embodiment.
  • any measuring method can be used to determine the grain size, provided that the grain size is determined by a uniform method.
  • the per se known line-cutting method is used to determine the mean grain size.
  • the transition region with the continuously changing average grain size can be produced by a PVD method, in particular by sputtering, by continuously changing the process parameters of the sputtering method that determine the mean grain size.
  • the layers may, for example, be realized in the form of lattice structures, in particular in the form of webs of a stent which have radially inward a first region of a first grain size and radially outward in the form of a cladding a second region of a second different grain size.
  • the radially outwardly disposed second area completely encloses the first area.
  • the outer and inner regions or layers have different grain sizes.
  • correspondingly embodied grid structures have a core area (first area) which is enveloped on the outside by a second area, the two areas having different grain sizes. It is also possible to arrange several outer layers around the core area, each having different grain sizes. All features of the other embodiments disclosed in this application, in particular all grain size features, are also disclosed and claimed in the context of this embodiment.
  • the embodiment with the fully enclosed inner region of the web or the lattice structure can also be advantageous in combination with graded layers, that is, with continuous material transitions.
  • the cladding of a core layer or a core area has the advantage, in contrast to laminated layers in which the sides of the layers are accessible, that a uniform corrosion behavior and thus a controllable dissolution rate are established. For laminates that are open on one side (laminate), corrosion can take place between the layers.
  • the concept of the coated regions or layers having different particle sizes is generally applicable to latticed implants in which a part of the lattice structure or a part of the elements forming the lattice structure is designed as explained above.
  • the elements may include lands, connectors, bridges or other elongated, curved or straight elements of the grid structure.
  • the coated layers can be produced, for example, by the process for producing structured layers according to DE 10 2006 029 831, the contents of which are incorporated by reference in their entirety into this application.
  • a first layer having a first grain size is applied, inter alia, to a substrate or to a composite of sacrificial layers.
  • a second layer is applied with a different grain size, which is patterned for example by etching such that only the second layer is partially removed on both sides.
  • the first lower layer projects laterally beyond the second upper layer on both sides.
  • a third layer having, for example, the same grain size as the first lower layer
  • the corresponding method according to DE 10 2006 029 831 is shown in FIGS. 12 to 17.
  • PVD processes in particular sputtering processes, which are particularly suitable for producing the different layers having the different particle sizes.
  • At least two regions of crystalline material with different particle sizes are provided for setting different dissolution rates of the different regions.
  • the different areas can be arranged in the radial direction of the elements, ie generally in the thickness direction and / or in the longitudinal direction.
  • the different regions with the different grain sizes may consist of the same material, in particular magnesium or a magnesium alloy. Suitable magnesium alloys are known to the person skilled in the art. It is also possible to use different materials for the different areas. Both alternatives are disclosed in connection with all embodiments and in connection with the invention in general.
  • the implant may comprise stents or stent-like implants, filters, in particular filters with a stent-like holding section, flow dividers, occluders, coils, or devices which minimize the blood flow or guide it to other collateral vessels, for example umbrellas.
  • the body of the implant may have a lattice structure.
  • the grid structure may comprise a laser-cut or a braided grid structure. In the latter case, wires form the body of the implant.
  • the body of the implant can also form a functional element of the implant, for example a filter section.
  • the grid structure or the body can form a wall of the implant.
  • the implant wall can be curved and, in particular, can be adapted to come into contact with a vessel wall, at least in regions, when the implant is inserted into a vessel.
  • the implant can also be a graft in which either the cover or the grid structure or both consist of the biodegradable material. It may also be that the cover and the grid structure have different grain sizes. However, it may also be that the different area both occur in the coverage area or in the grid structure. It is also possible to use the invention in orthopedic implants.
  • the invention can be applied to the entire implant or to a part of the implant. For example. In the case of a stent combined with a filter, it is possible to control the dissolution rate such that only the filter, or in general only the functional element, dissolves after the end of the application.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)

Abstract

L'invention concerne un implant médical comprenant un corps (10) qui est constitué au moins par endroits d'au moins un matériau cristallin biodégradable. L'invention est caractérisée en ce que le corps (10) comprend au moins une première et une deuxième zone (11, 12) différentes, le matériau cristallin de la première zone (11) ayant une taille de grains différente de celle du matériau cristallin de la deuxième zone (12).
EP10700942A 2009-01-09 2010-01-11 Implant médical et procédé de production d'un tel implant Withdrawn EP2385846A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE200910004188 DE102009004188A1 (de) 2009-01-09 2009-01-09 Medizinisches Implantat und Verfahren zur Herstellung eines solchen Implantats
PCT/EP2010/000088 WO2010079145A2 (fr) 2009-01-09 2010-01-11 Implant médical et procédé de production d'un tel implant

Publications (1)

Publication Number Publication Date
EP2385846A2 true EP2385846A2 (fr) 2011-11-16

Family

ID=42091511

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10700942A Withdrawn EP2385846A2 (fr) 2009-01-09 2010-01-11 Implant médical et procédé de production d'un tel implant

Country Status (3)

Country Link
EP (1) EP2385846A2 (fr)
DE (1) DE102009004188A1 (fr)
WO (1) WO2010079145A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010027124A1 (de) * 2010-07-14 2012-01-19 Acandis Gmbh & Co. Kg Medizinisches Implantat und Verfahren zur Herstellung eines solchen Implantats
WO2012025245A1 (fr) 2010-08-26 2012-03-01 Acandis Gmbh & Co. Kg Électrode pour utilisations médicales, système comportant une électrode et procédé de fabrication d'une électrode
CN204542477U (zh) * 2015-02-10 2015-08-12 东莞颠覆产品设计有限公司 一种多层可扩张血管支架

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1959025A1 (fr) * 2005-11-16 2008-08-20 National Institute for Materials Science Materiau metallique biodegradable a base de magnesium

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4542539A (en) * 1982-03-12 1985-09-24 Artech Corp. Surgical implant having a graded porous coating
DE59913189D1 (de) * 1998-06-25 2006-05-04 Biotronik Ag Implantierbare, bioresorbierbare Gefässwandstütze, insbesondere Koronarstent
DE19945049A1 (de) * 1999-09-20 2001-03-22 Meyer Joerg Durch Korrosion abbaubare medizinische Implantate aus Wolframlegierungen
US6537310B1 (en) * 1999-11-19 2003-03-25 Advanced Bio Prosthetic Surfaces, Ltd. Endoluminal implantable devices and method of making same
US6379383B1 (en) * 1999-11-19 2002-04-30 Advanced Bio Prosthetic Surfaces, Ltd. Endoluminal device exhibiting improved endothelialization and method of manufacture thereof
ATE306953T1 (de) * 2001-01-05 2005-11-15 Jacqueline Yvonne Hausdorf Durch korrosion abbaubare metallische medizinische implantate
DE10128100A1 (de) * 2001-06-11 2002-12-19 Hannover Med Hochschule Medizinisches Implantat für den menschlichen und tierischen Körper
US7048767B2 (en) * 2002-06-11 2006-05-23 Spire Corporation Nano-crystalline, homo-metallic, protective coatings
US7344560B2 (en) * 2004-10-08 2008-03-18 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
DE102005018356B4 (de) 2005-04-20 2010-02-25 Eurocor Gmbh Resorbierbare Implantate
US20070050009A1 (en) 2005-08-30 2007-03-01 Aiden Flanagan Bioabsorbable stent
US20070151638A1 (en) * 2005-12-29 2007-07-05 Robert Burgermeister Method to develop an organized microstructure within an implantable medical device
US8840660B2 (en) * 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
DE102006029831A1 (de) 2006-06-27 2008-01-03 Acandis Gmbh & Co. Kg Verfahren zur Herstellung strukturierter Schichten aus Titan und Nickel
DE102009023371A1 (de) 2009-05-29 2010-12-02 Acandis Gmbh & Co. Kg Verfahren zur Herstellung eines medizinischen Funktionselements mit einer freitragenden Gitterstruktur

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1959025A1 (fr) * 2005-11-16 2008-08-20 National Institute for Materials Science Materiau metallique biodegradable a base de magnesium

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2010079145A2 *

Also Published As

Publication number Publication date
WO2010079145A3 (fr) 2010-11-18
DE102009004188A1 (de) 2010-07-15
WO2010079145A8 (fr) 2011-02-17
WO2010079145A2 (fr) 2010-07-15

Similar Documents

Publication Publication Date Title
EP2678466B1 (fr) Implant équipé de non-tissé
DE69829015T2 (de) Wirkstoffhaltige poröse Metallprothesen
EP2698130B1 (fr) Procédé de fabrication d'un implant corporel
DE10150995A1 (de) Implantat mit proliferationshemmender Substanz
EP1984033B1 (fr) Procédé d'enveloppement d'un stent
EP3463206A1 (fr) Traitement d'un angiospasme
EP3930777B1 (fr) Élément fonctionnel intravasculaire, système comprenant un élément fonctionnel, et procédé
EP2563285B1 (fr) Procédé de fabrication d'un dispositif médical
EP2385846A2 (fr) Implant médical et procédé de production d'un tel implant
WO2019174991A1 (fr) Fermeture temporaire de collets d'anévrisme
EP2593151A1 (fr) Implant médical et procédé de fabrication d'un tel implant
WO2023104590A1 (fr) Implant pour le traitement d'anévrismes dans la zone de bifurcations
EP4164554B1 (fr) Implant pour traiter des anévrismes
DE102021128698B4 (de) Implantat, insbesondere Stent, und Herstellungsverfahren
DE102007029672A1 (de) Implantat und Verfahren zu dessen Herstellung
DE102014111117B4 (de) Medizinische Vorrichtung zur Behandlung von neurovaskulären Erkrankungen, System und Set mit einer derartigen Vorrichtung sowie Herstellungsverfahren
DE102021102458A1 (de) Beschichtete medizinische Vorrichtungen
EP3952798B1 (fr) Stent
WO2014067656A1 (fr) Stent biorésorbable constitué d'un matériau composite
EP3643337B1 (fr) Stent pour l'implantation dans une cavité d'un corps humain ou animal ainsi que procédé de fabrication d'une structure de couches opaque aux rayons x sur un stent
WO2023006537A1 (fr) Implant, en particulier stent, et procédé de fabrication
EP4284309A1 (fr) Dispositifs médicaux revêtus
DE102007032338A1 (de) Implantat, insbesondere Stent, und Verfahren zur Herstellung eines derartigen Implantats, insbesondere Stents
EP1389135A1 (fr) Dispositif medical

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110804

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20120816

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160802